BIOCON

What Biocon promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 22 tracked 12 delivered 2 missed 8 open
  • Biosimilars EBITDA Margin delivered said Q3 FY25 Promised: Sustainable guidance of 22% to 23% Q1 FY27: 25% margin reported, in line with 'mid-20s' guidance.
  • Syngene (CRDMO) Revenue Growth missed said Q2 FY26 Promised: Maintaining annual guidance for FY26 Q1 FY27: Promise related to FY26 guidance remains missed. New guidance for FY27 is for single-digit revenue degrowth.
  • Generics EBITDA Margin at risk said Q3 FY25 Promised: Get closer to 13%, 14% in 1 or 2 years Q1 FY27: Margin reported at 7%, a sequential decline from 8% in Q4 FY26. Remains far from the 13-14% target.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 22 tracked commitments for Biocon — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens